Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
MaxCyte ( (MXCT) ) just unveiled an update.
MaxCyte, Inc. has signed a strategic platform license with TG Therapeutics to advance its autoimmune cell therapeutics programs. This agreement allows TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in developing and commercializing azer-cel, a CD19 CAR T cell therapy for autoimmune diseases. This partnership is expected to bolster MaxCyte’s role in the cell engineering sector and support TG Therapeutics’ progression towards a Phase 1 clinical trial for multiple sclerosis treatment, potentially enhancing both companies’ positions in their respective fields.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, specializing in platform technologies for the discovery, development, and commercialization of next-generation cell-based therapeutics. Their ExPERT™ platform, based on Flow Electroporation® technology, supports the cell therapy market from discovery to commercialization. The company has over 25 years of experience in enhancing cell engineering processes.
YTD Price Performance: 4.94%
Average Trading Volume: 53,160
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £369.4M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.
